Benzinga

Benzinga

Benzinga

lunes, agosto 31

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$247.91
-1.45-0.58%
al cierre: Aug 28, 5:00 PM EST
$247.91
N/A
After hour: Aug 28, 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 11 Quarters

Analyst Consensus — 19 Analysts

1S.Buy
18Buy
Consensus RatingBuy# Analysts19Avg. Consensus PT$289Upside to Avg. PT+16.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026HC Wainwright & Co.Mitchell S. KapoorInitiateBuy$345
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$319
More with Benzinga EdgeGet Access

Analyst Ratings News

This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.
Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved